	US 12,441,803 B2
	Engineered CD25 polypeptides and uses thereof
Matthew P. Greving, San Carlos, CA (US); Phung Tu Gip, San Francisco, CA (US); Mohan Srinivasan, Cupertino, CA (US); Andrew Morin, San Mateo, CA (US); Kevin Eduard Hauser, Jupiter, FL (US); Jordan R. Willis, Hayward, CA (US); Cody A. Moore, San Francisco, CA (US); Christian Barrett, San Diego, CA (US); Alex T. Taguchi, San Mateo, CA (US); and Angeles Estelles, Belmont, CA (US)
Assigned to iBio, Inc., San Diego, CA (US)
Filed by iBio, Inc., Bryan, TX (US)
Filed on May 13, 2021, as Appl. No. 17/320,118.
Application 17/320,118 is a continuation of application No. PCT/US2019/061567, filed on Nov. 14, 2019.
Claims priority of provisional application 62/902,334, filed on Sep. 18, 2019.
Claims priority of provisional application 62/767,431, filed on Nov. 14, 2018.
Prior Publication US 2023/0016112 A1, Jan. 19, 2023
Int. Cl. C07K 16/28 (2006.01)

CPC C07K 16/2866 (2013.01) [C07K 2317/34 (2013.01); C07K 2317/565 (2013.01)]

10 Claims

1. An engineered polypeptide, wherein the engineered polypeptide shares at least 80% structural and/or dynamic identity to an α-subunit of an IL-2 receptor (CD25) reference target, wherein the CD25 reference target is a portion of CD25 selected from:


Reference
Target No.	CD25 Residues	Sequence

1	55-63	SWDNQCQCT (SEQ ID NO:
		22)

2	13-20:127-132	ATFKAMA (SEQ ID NO:
		23):MVYYQC (SEQ ID NO:
		24)

3	5-17	DDPPEIPHATFKA (SEQ ID
		NO: 25)

4	5-11:156-163	DDPPEIP (SEQ ID NO:
		26):RWTQPQLI (SEQ ID
		NO: 27)

5	77-89	QPEEQKERKTTEM (SEQ ID
		NO: 28)

6	147-157	VCKMTHGKTRW (SEQ ID
		NO: 29)

7	11-14	IPHA (SEQ ID NO: 30).